• Minicabecera4

Histocell, selected for the TechShare program, considers listing in Euronext

 MG 2959 web

Euronext, the leading pan-European Exchange in the Eurozone, was present at BIOSPAIN, the largest biotechnology event organised by a national association of the sector in Europe, which took place in Seville from September 25 to 27. The exchange has launched its fourth session of TechShare, the only European programme for non-listed companies dedicated to IPOs.

TechShare was launched in Paris in September and, for the first time, nine Spanish companies were selected to participate. Accompanied by Ability Pharma and Histocell, two of the Spanish biotechnology companies participating in the program, Susana de Antonio, director of Euronext in Spain, highlighted the "success" of this year's edition and the strength of the Spanish SME sector to strengthen its reputation international.

This fourth edition of the TechShare program has the presence of several leaders of the Spanish technological landscape, such as Fon, Anfix or Babel, as well as the telecommunications sector, such as CaseOnIt. In addition, these participants attended the first session in Paris with some leading biotechnology companies in the country, such as Ability Pharma, Minoryx Therapeutics, SOM Biotech and Histocell.

One of the highlights of BIOSPAIN this year is, precisely, the round table that addressed the opportunities that international capital markets could provide to Spanish biotechnology companies. Several experts, including Susana de Antonio, analysed how the stock markets can work as platforms that facilitate greater growth and liquidity, as well as greater visibility and independence with respect to private investors.

"Spain is the second country with the most biotechnology companies in the world and in BIOSPAIN we clearly perceive how our biotechnology companies are setting the course in Europe," said Susana de Antonio, Euronext's director in Spain. "In 2017, investment in technology companies in Spain grew more than 50%, so it is no coincidence that several Spanish biotechnology companies are among the participants of the TechShare program with the aim of preparing for the next stage of growth".

Organised as an educational network, its aim is to help businesses with great potential to understand the role of capital markets, and how these can help them move on to the next phase of their growth. The TechShare program offers training in different areas to nine Spanish companies and it creates unique networking opportunities in sectors such as banking, legislation and audits, financial communication, technology and research.

This first session that took place in Paris will be followed by adapted coaching meetings to be held in each country and will be led by some 80 expert partners hired by Euronext.

Julio Font, CEO of Histocell, one of the veteran companies in BIOSPAIN, said: "In our case, starting to list is an attractive option to gain visibility in Europe that allows us, at the same time, to access a wide network of international investors".

About Euronext

Euronext is the most important pan-European stock market in the Eurozone. It includes Belgium, France, Ireland, the Netherlands, Portugal and the United Kingdom. With almost 1,300 listed issuers and an approximate value of 3.9 billion euros in market capitalisation at the end of June 2018, Euronext is an exemplary and first-line franchise that has 24 issuers in the Morningstar® Eurozone 50 Index℠ index and one solid and varied base of national and international clients.